相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER2 aberrations in cancer: Implications for therapy
Min Yan et al.
CANCER TREATMENT REVIEWS (2014)
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
Daniele Cretella et al.
MOLECULAR CANCER (2014)
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
Baris Boyraz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Targeting the ERBB family in cancer: couples therapy
Niall Tebbutt et al.
NATURE REVIEWS CANCER (2013)
Carcinosarcoma of the ovary: A review of the literature
Marcela G. del Carmen et al.
GYNECOLOGIC ONCOLOGY (2012)
HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas
Federica Guzzo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
Manish Gupta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pathology of mixed Mullerian tumours
Emanuela D'Angelo et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2011)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Mark Barok et al.
CANCER LETTERS (2011)
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
K. El-Sahwi et al.
BRITISH JOURNAL OF CANCER (2010)
Ovarian and Uterine Carcinosarcomas A Comparative Analysis of Prognostic Variables and Survival Outcomes
Gunjal Garg et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
The role of HER2 in cancer therapy and targeted drug delivery
Wanyi Tai et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Carcinosarcoma of the Ovary A Review
Leigh A. Cantrell et al.
OBSTETRICAL & GYNECOLOGICAL SURVEY (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Unraveling the Biologic and Clinical Complexities of HER2
John W. Park et al.
CLINICAL BREAST CANCER (2008)
Uterine carcinosarcoma: Immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets
David Cimbaluk et al.
GYNECOLOGIC ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Current management of ovarian carcinosarcoma
M. S. Mano et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
Zsolt Gabos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical features and outcomes of uterine and ovarian carcinosarcoma
AL Jonson et al.
GYNECOLOGIC ONCOLOGY (2006)
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma
CA Livasy et al.
GYNECOLOGIC ONCOLOGY (2006)
Amplification of c-erbB2 oncogene - A maior prognostic indicator in uterine serous papillaty carcinoma
AD Santin et al.
CANCER (2005)
COX-2, c-KIT and HER-2/neu expression in uterine carcino sarcomas: prognostic factors or potential markers for targeted therapies?
MR Raspollini et al.
GYNECOLOGIC ONCOLOGY (2005)
Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989-1999
BE Brooks et al.
GYNECOLOGIC ONCOLOGY (2004)
ERBB-2 gene overexpression and amplification in uterine sarcomas
F Amant et al.
GYNECOLOGIC ONCOLOGY (2004)
Malignant mixed mullerian tumour of the ovary: Prognostic factor and response of adjuvant platinum-based chemotherapy
P Inthasorn et al.
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY (2003)
Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma
M Sawada et al.
CANCER SCIENCE (2003)
Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas
WG McCluggage
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2002)
Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?
WG McCluggage
JOURNAL OF CLINICAL PATHOLOGY (2002)
分享论文
